Poviztra 0.25mg FlexTouch uses are:

• Long-term weight management in adults with obesity (BMI of 30 or more)

• Weight management in adults with a BMI of 27 or more who also have weight-related health issues like type 2 diabetes, high blood pressure, or high cholesterol

Poviztra 0.25mg FlexTouch supports weight loss by mimicking natural hormones that regulate hunger. As a GLP-1 medication, it sends signals to your brain that you are full, helping you feel satisfied after smaller meals. It also slows down the movement of food through your stomach, which prolongs fullness and reduces cravings.

Poviztra 0.25mg FlexTouch influences GIP, another hormone involved in metabolism, which can help improve how your body handles nutrients and supports weight management.

Using a GLP-based approach like Poviztra 0.25mg FlexTouch provides consistent appetite control over time. Results appear gradually, allowing you to eat less without feeling deprived, which is essential for sustainable, long-term weight loss.

1. Insulin and Insulin Analogues (Injection Route) Moderate
   Concurrent use may increase the risk of low blood sugar. Dose adjustment and regular blood glucose monitoring may be required.

2. Sulfonylureas such as Glimepiride or Glyburide (Oral Route) Moderate
   Using together can raise the risk of hypoglycemia. Doctors may reduce the dose of the sulfonylurea and monitor blood sugar closely.

3. Metformin (Oral Route) Mild
   Generally safe when used together. Routine monitoring of blood glucose levels is recommended.

4. DPP 4 Inhibitors such as Sitagliptin or Vildagliptin (Oral Route) Mild
   No clinically significant interaction is expected, but combined glucose lowering effects should be monitored.

5. Warfarin (Oral Route) Mild
   Semaglutide may indirectly affect clotting control due to changes in blood glucose or body weight. Periodic monitoring of INR is advised.

• Store your pen in the fridge (not the freezer), it should be kept between 2°C and 8°C.

• If you forget a dose, take it within 5 days. If it’s been longer, skip that dose and stick to your regular schedule.

• Never take two doses at once to make up for a missed one.

• Signs of overdose (like severe nausea or vomiting) need medical attention right away.

• Always keep the pen out of children’s reach and don’t share it, even if the needle is changed.

Poviztra 0.25mg FlexTouch, a GLP-1–based medication, is given once a week as an injection under the skin. You can inject it in your stomach, thigh, or upper arm, just rotate spots to avoid irritation. It can be taken with or without food.

For consistent results, use it on the same day each week. Your doctor or nurse will guide you on how to safely use this injection pen, ensuring proper technique and effectiveness.

Poviztra 0.25mg FlexTouch causes some side effects like all medications, although not everyone will experience them. 

Common side effects:

• Nausea

• Vomiting

• Constipation or diarrhoea

• Tiredness

• Headache

• Indigestion

• Bloating or gas

Serious side effects (get medical help if you notice these):

• Severe stomach pain or signs of pancreatitis

• Gallbladder issues (like pain in your upper belly or yellowing of the skin)

• Signs of kidney problems (such as less urination or swelling)

• Fast heart rate

• Allergic reactions (rash, itching, swelling, trouble breathing)

• Stick to a Weekly Routine: Take Poviztra 0.25mg FlexTouch on the same day each week. Use phone reminders or calendar alerts to avoid missing a dose.

• Rotate Injection Sites: To prevent skin irritation or lumps, inject into different spots on your abdomen, thigh, or upper arm each time.

• Manage Nausea Smartly: Eat small, balanced meals and avoid greasy or high-fat foods. This can help reduce nausea and improve digestion.

• Stay Hydrated: Drink plenty of water throughout the day to prevent dehydration, especially if you experience nausea, vomiting, or diarrhoea.

• Watch for Warning Signs: If you notice severe stomach pain, vomiting, or signs of an allergic reaction, seek medical help immediately. These could be signs of serious side effects like pancreatitis.

1. Novo Nordisk Inc, FDA Food and Drug Safety Administration [September 20, 2019] [Accessed date 18th August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209637s032lbl.pdf

2. Novo Nordisk Limited, EMC,  [25 Jan 2023], [Accessed date 18th August 2023] Electronic Medicines Compendium (EMC), [Revised on 25th Jan 2023] [Accessed on 18 August 2023] https://www.ema.europa.eu/en/documents/overview/ozempic-epar-summary-public_en.pdf

3. https://cdscoonline.gov.in/CDSCO/cdscoDrugs